{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:59:40Z","timestamp":1790117980615,"version":"4.0.1"},"reference-count":25,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The phase 2 ALYCANTE trial aimed to evaluate the investigator-assessed complete metabolic response at 3 months from the axicabtagene ciloleucel (axi-cel) infusion as a primary end point in patients with high-risk relapsed\/refractory large B-cell lymphoma who are ineligible for autologous stem cell transplantation (ASCT). This study showed a significant improvement in complete metabolic response rate at 3 months based on historical controls. This study reports the health-related quality of life (HRQoL) results as a secondary end point. HRQoL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) cancer-specific questionnaire, the Quality of Life Questionnaire high-grade non-Hodgkin lymphoma 29 (QLQ-NHL-HG29) , and the EuroQol Quality of Life Scale-5 dimensions-5 levels of severity (EQ-5D-5L) generic questionnaire at baseline and 1, 3, 6, and 12 months after axi-cel infusion. Among the 62 patients included, 60 (97%) completed a baseline and at least 1 postbaseline HRQoL assessment. At 1 month infusion, adjusted mean change in HRQoL scores from baseline showed a clinically significant deterioration (greater than the clinical threshold) in physical, role, social functioning, and fatigue. However, all HRQoL dimensions recovered by 3 months after infusion and remained stable or continued to improve by 12 months. In an exploratory analysis, adjusted mean change in HRQoL score from baseline in ALYCANTE was similar to or better than in ASCT-eligible patients who received axi-cel in the phase 3 ZUMA-7 trial. Finally, the global health status and fatigue scores of the ALYCANTE population improved to levels comparable to the general French population of similar age by 3 months after infusion. These findings indicate that axi-cel improves HRQoL regardless of transplant eligibility, supporting its use across a broad patient population. This trial was registered at www.clinicaltrials.gov as #NCT04531046.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018057","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:18:10Z","timestamp":1767989890000},"page":"1773-1782","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphoma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0259-8811","authenticated-orcid":false,"given":"Emilie","family":"Charton","sequence":"first","affiliation":[{"name":"1Department of Clinical Research and Innovation, Centre L\u00e9on B\u00e9rard, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6896-1367","authenticated-orcid":false,"given":"Am\u00e9lie","family":"Anota","sequence":"additional","affiliation":[{"name":"1Department of Clinical Research and Innovation, Centre L\u00e9on B\u00e9rard, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2694-7510","authenticated-orcid":false,"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Lyon Sud Hospital, INSERM U1111, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0659-9635","authenticated-orcid":false,"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[{"name":"3Department of Hematology, University Hospital of Montpellier, CNRS UMR 5535, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8998-3039","authenticated-orcid":false,"given":"Fran\u00e7ois-Xavier","family":"Gros","sequence":"additional","affiliation":[{"name":"4Department of Clinical Hematology and Cellular Therapy, University Hospital of Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[{"name":"5ULR 7365, Groupe de Recherche sur les formes Injectables et les Technologies Associ\u00e9es, University Hospital of Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0039-1983","authenticated-orcid":false,"given":"Lucie","family":"Oberic","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Cancer University Institute of Toulouse Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gastinne","sequence":"additional","affiliation":[{"name":"7Department of Hematology, University Hospital of Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Feugier","sequence":"additional","affiliation":[{"name":"8Department of Hematology, University Hospital of Nancy, INSERM 1256, University of Lorraine, Vandoeuvre-l\u00e8s-Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5024-1713","authenticated-orcid":false,"given":"Remy","family":"Dulery","sequence":"additional","affiliation":[{"name":"9Department of Clinical Hematology and Cellular Therapy, Sorbonne University, Saint-Antoine Hospital, Assistance Publique-H\u00f4pitaux de Paris, INSERM UMR938, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[{"name":"10Department of Hematology and Oncology, Saint-Louis Hospital, Assistance Publique-H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magalie","family":"Joris","sequence":"additional","affiliation":[{"name":"11Department of Hematology, University Hospital of Amiens, Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Jardin","sequence":"additional","affiliation":[{"name":"12Department of Clinical Hematology, Henri Becquerel Center, INSERM U1245, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7791-0470","authenticated-orcid":false,"given":"Sylvain","family":"Choquet","sequence":"additional","affiliation":[{"name":"13Department of Hematology, University Hospital Piti\u00e9 Salp\u00eatri\u00e8re, Assistance Publique-H\u00f4pitaux de Paris, Sorbonne University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1156-8983","authenticated-orcid":false,"given":"Olivier","family":"Casasnovas","sequence":"additional","affiliation":[{"name":"14Department of Clinical Hematology, Dijon University Hospital, INSERM UMR 1231, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0771-683X","authenticated-orcid":false,"given":"Gabriel","family":"Brisou","sequence":"additional","affiliation":[{"name":"15Department of Hematology, Institut Paoli-Calmettes, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Cheminant","sequence":"additional","affiliation":[{"name":"16Department of Clinical Hematology, Necker-Enfants Malades University Hospital, Assistance Publique-H\u00f4pitaux de Paris, INSERM UMR 1163, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Olivier","family":"Bay","sequence":"additional","affiliation":[{"name":"17Department of Clinical Hematology and Cellular Therapy, Clermont-Ferrand University Hospital Center, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Llamas Gutierrez","sequence":"additional","affiliation":[{"name":"18Department of Anatomopathology, University Hospital of Rennes, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Portugues","sequence":"additional","affiliation":[{"name":"19Department of Biostatistics, Lymphoma Study Association Clinical Research, Lyon-Sud Hospital, Pierre-B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1578-4058","authenticated-orcid":false,"given":"Emmanuel","family":"Itti","sequence":"additional","affiliation":[{"name":"20Department of Nuclear Medicine, Henri Mondor Hospital, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Palard-Novello","sequence":"additional","affiliation":[{"name":"21Department of Nuclear Medicine, University of Rennes, Cancer Care Centre Eug\u00e8ne Marquis, INSERM U1099, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Blanc-Durand","sequence":"additional","affiliation":[{"name":"20Department of Nuclear Medicine, Henri Mondor Hospital, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yassine","family":"Al Tabaa","sequence":"additional","affiliation":[{"name":"22Scintidoc Nuclear Medicine Center, Clinique Cl\u00e9mentville, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Bailly","sequence":"additional","affiliation":[{"name":"23Nantes-Angers Cancer Research Center, University of Nantes, INSERM UMR 1307, CNRS ERL6075, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Laurent","sequence":"additional","affiliation":[{"name":"24Department of Pathology, CHU Toulouse Oncopole, University Hospital of Toulouse, CRCT INSERM U1037, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Lemonnier","sequence":"additional","affiliation":[{"name":"25Lymphoid Malignancies Unit, Henri Mondor Hospital, Mondor Institute for Biomedical Research, INSERM U955, University Paris-Est, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-8213","authenticated-orcid":false,"given":"Roch","family":"Houot","sequence":"additional","affiliation":[{"name":"26Department of Hematology, University Hospital of Rennes, UMR U1236, INSERM, University of Rennes, French Blood Establishment, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"issue":"26","key":"2026030916163105100_bib1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2026030916163105100_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"2026030916163105100_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11912-021-01161-4","article-title":"Engineered T cells: CAR T cell therapy and beyond","volume":"24","author":"Johnson","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"2026030916163105100_bib4","unstructured":"YESCARTA (axicabtagene ciloleucel). Prescribing information. Kite. 2024. Accessed 22 January 2026. https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/oncology\/yescarta\/yescarta-pi.pdf."},{"issue":"7","key":"2026030916163105100_bib5","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"2026030916163105100_bib6","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): B-Cell Lymphomas Version 1.2025","year":"2024"},{"issue":"10","key":"2026030916163105100_bib7","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1038\/s41591-023-02572-5","article-title":"Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial","volume":"29","author":"Houot","year":"2023","journal-title":"Nat Med"},{"issue":"20","key":"2026030916163105100_bib8","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1002\/cncr.30173","article-title":"Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma","volume":"122","author":"Chihara","year":"2016","journal-title":"Cancer"},{"key":"2026030916163105100_bib9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.21037\/aol-22-2","article-title":"Diffuse large B-cell lymphoma among the elderly: a narrative review of current knowledge and future perspectives","volume":"6","author":"W\u00e4sterlid","year":"2022","journal-title":"Ann Lymphoma"},{"issue":"2","key":"2026030916163105100_bib10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00277-021-04689-4","article-title":"Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study","volume":"101","author":"Paunescu","year":"2022","journal-title":"Ann Hematol"},{"issue":"21","key":"2026030916163105100_bib11","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood.2022015478","article-title":"Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma","volume":"140","author":"Elsawy","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2026030916163105100_bib12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"17","key":"2026030916163105100_bib13","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1002\/cncr.34822","article-title":"International validation of two EORTC questionnaires for assessment of health-related quality of life for patients with high-grade non-Hodgkin lymphoma (QLQ-NHL-HG29) and low-grade non-Hodgkin lymphoma (QLQ-NHL-LG20)","volume":"129","author":"Oerlemans","year":"2023","journal-title":"Cancer"},{"issue":"10","key":"2026030916163105100_bib14","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"1","key":"2026030916163105100_bib15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s41687-024-00719-7","article-title":"General population normative values for the EORTC QLQ-C30 by age, sex, and health condition for the French general population","volume":"8","author":"Pilz","year":"2024","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"2026030916163105100_bib16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"2026030916163105100_bib17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Outcomes"},{"issue":"8","key":"2026030916163105100_bib18","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"issue":"3","key":"2026030916163105100_bib19","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3324\/haematol.2023.283162","article-title":"Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study","volume":"109","author":"Gordon","year":"2024","journal-title":"Haematologica"},{"issue":"12","key":"2026030916163105100_bib20","doi-asserted-by":"crossref","first-page":"e802","DOI":"10.1097\/HS9.0000000000000802","article-title":"Chimeric antigen receptor T-cell therapy in hematologic malignancies and patient-reported outcomes: a scoping review","volume":"6","author":"Efficace","year":"2022","journal-title":"Hemasphere"},{"issue":"8","key":"2026030916163105100_bib21","first-page":"2401","article-title":"Health-related quality of life in patients with hematologic malignancies treated with chimeric antigen receptor T-cell therapy: review and current progress","volume":"109","author":"Tchernonog","year":"2024","journal-title":"Haematologica"},{"issue":"10","key":"2026030916163105100_bib22","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jtct.2025.06.030","article-title":"Assessing quality of life and symptoms in transplantation and CAR-T recipients: expert panel recommendations from the survivorship special interest group of ASTCT","volume":"31","author":"Banerjee","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"3-4","key":"2026030916163105100_bib23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000324707","article-title":"Cross-trial comparisons in the oncology arena: when is this justified?","volume":"80","author":"Markman","year":"2011","journal-title":"Oncology"},{"issue":"9","key":"2026030916163105100_bib24","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1093\/annonc\/mdx191","article-title":"How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials","volume":"28","author":"Bonnetain","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"2026030916163105100_bib25","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12874-019-0717-9","article-title":"Assessments of attrition bias in Cochrane systematic reviews are highly inconsistent and thus hindering trial comparability","volume":"19","author":"Babic","year":"2019","journal-title":"BMC Med Res Methodol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1773\/2506713\/blooda_adv-2025-018057-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1773\/2506713\/blooda_adv-2025-018057-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T20:16:39Z","timestamp":1773087399000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/5\/1773\/565938\/Health-related-quality-of-life-after-second-line"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018057","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,10]]},"published":{"date-parts":[[2026,3,2]]}}}